Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
Hongge Liang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jing Zhao(University of Electronic Science and Technology of China), Minjiang Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Wei Zhong(Chinese Academy of Medical Sciences & Peking Union Medical College), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 24
Related Papers
Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19)
|Clinical Infectious Diseases|2020|556
Efficacy and safety of Paxlovid in severe adult patients with SARS-Cov-2 infection: a multicenter randomized controlled study
|The Lancet Regional Health - Western Pacific|2023|112
<p>MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis</p>
|OncoTargets and Therapy|2020|111
HIF-2α-targeted interventional chemoembolization multifunctional microspheres for effective elimination of hepatocellular carcinoma
|Biomaterials|2022|68
PI3K in Cancer: Its Structure, Activation Modes and Role in Shaping Tumor Microenvironment
|Future Oncology|2017|65